PubMed Health. A service of the National Library of Medicine, National Institutes of Health.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.
A.D.A.M. Medical Encyclopedia.
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. The uvea provides most of the blood supply to the retina.
Causes, incidence, and risk factors
Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. However, in many cases the cause is unknown.
The most common form of uveitis is anterior uveitis, which involves inflammation in the front part of the eye. It is often called iritis because it usually only affects the iris, the colored part of the eye. The inflammation may be associated with autoimmune diseases, but most cases occur in healthy people. The disorder may affect only one eye. It is most common in young and middle-aged people.
Posterior uveitis affects the back part of the uvea, and involves primarily the choroid, a layer of blood vessels and connective tissue in the middle part of the eye. This type of uveitis is called choroiditis. If the retina is also involved, it is called chorioretinitis. You may develop this condition if you have had a body-wide (systemic) infection or if you have an autoimmune disease.
Another form of uveitis is pars planitis. This inflammation affects the narrowed area (pars plana) between the colored part of the eye (iris) and the choroid. Pars planitis usually occurs in young men and is generally not associated with any other disease. However, some evidence suggests it may be linked to Crohn's disease and possibly multiple sclerosis.
Uveitis can be associated with any of the following:
- Ankylosing spondylitis
- Behcet syndrome
- Injury
- Rheumatoid arthritis
- Syphilis
Symptoms
Uveitis can affect one or both eyes. Symptoms may develop rapidly and can include:
- Dark, floating spots in the vision
Signs and tests
A complete medical history and eye examination should be performed. Laboratory tests may be done to rule out infection or an autoimmune disorder.
Persons over age 25 with pars planitis should have an MRI of their brain and spine to rule out multiple sclerosis.
Treatment
Iritis is usually mild. Treatment may involve:
- Dark glasses
- Eye drops that dilate the pupil to relieve pain
- Steroid eye drops
Pars planitis is often treated with steroid eye drops. Other medicines, including steroids taken by mouth, may be prescribed to help suppress the immune system.
Posterior uveitis treatment depends on the underlying cause but almost always includes steroids taken by mouth. Additional specialists in infectious disease or autoimmunity may be needed for such diseases as syphilis, tuberculosis, AIDS, sarcoidosis, or Behcet syndrome.
If the uveitis is caused by a body-wide infection, treatment may involve antibiotics and powerful anti-inflammatory medicines called corticosteroids. See autoimmune disorders for information on treating such diseases.
Expectations (prognosis)
With proper treatment, most attacks of anterior uveitis go away in a few days to weeks. However, relapses are common.
Inflammation related to posterior uveitis may last from months to years and may cause permanent vision damage, even with treatment.
Complications
- Fluid within the retina
Calling your health care provider
Call for an appointment with your health care provider if you have symptoms of uveitis. Eye pain or reduced vision are urgent symptoms that require prompt medical attention.
Prevention
Treatment of an underlying disorder may help to prevent uveitis in persons with a body-wide (systemic) infection or disease.
References
- Goldstein DA, Pyatetsky D, Tessler HH. Classification, symptoms, and signs of uveitis. In: Tasman W, Jaeger EA, eds. Duane’s Ophthalmology. 15th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2009:chap 32.
- Goldstein DA, Horsley M, Ulanski LJ II, Tessler HH. Complications of uveitis and their management. In: Tasman W, Jaeger EA, eds. Duane’s Ophthalmology. 15th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2009:chap 60.
- Cunningham ET Jr, Nozik RA. Uveitis: Diagnostic approach and ancillary analysis. In: Tasman W, Jaeger EA, eds. Duane’s Ophthalmology. 15th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2009:chap 37.
- Yanoff M, Cameron D. Diseases of the visual system. In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 431.
Review Date: 9/3/2012.
Reviewed by: Linda J. Vorvick, MD, Medical Director and Director of Didactic Curriculum, MEDEX Northwest Division of Physician Assistant Studies, Department of Family Medicine, UW Medicine, School of Medicine, University of Washington. Franklin W. Lusby, MD, Ophthalmologist, Lusby Vision Institute, La Jolla, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M. Health Solutions, Ebix, Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
Rifabutin for treating pulmonary tuberculosis
Among current challenges in tuberculosis treatment are reducing the length of time that drugs must be taken to less than six months and finding ways to safely combine tuberculosis drugs with those used in the treatment of HIV infection. Rifabutin is a drug that has the potential to address these issues if substituted for rifampicin, a mainstay of current treatment. This review identified five trials involving 924 people, but none were of high quality. The review found no significant differences between rifabutin‐ and rifampicin‐containing treatment in curing tuberculosis and preventing relapse, but higher doses of rifabutin might be associated with more adverse effects and there was no evidence that it could shorten treatment. However, very few people with HIV and tuberculosis, who are most likely to benefit from use of rifabutin due to its lack of interaction with antiretroviral drugs, were included in the trials. Better quality clinical trials are needed to understand the place of rifabutin in the treatment of people with tuberculosis, particularly those who also have HIV.
Tips for reading the newsDon’t automatically believe the headlines. Learn how to figure out which articles you’re going to believe and which you’re not.
- Uvea
- Sclera
- Retina
- Iris
- Ciliary body
- Choroid
- Autoimmune disorders
- Rheumatoid arthritis
- Ankylosing spondylitis
- Systemic
- Vision problems
- Macula lutea
- Toxoplasmosis
- Histoplasmosis
- Pulmonary tuberculosis
- Sarcoidosis
- AIDS
- Cytomegalovirus retinitis
- Ulcerative colitis
- Kawasaki disease
- Shingles
- Psoriasis
- Reactive arthritis
- Glaucoma
- Cataract
- Retinal detachment
- Ankylosing Spondylitis
- Behcet's Syndrome
- Eye Diseases
- Rheumatoid Arthritis
- Vision Impairment and Blindness
MedlinePlus.gov links to free, reliable, up-to-date health information from the National Institutes of Health (NIH) and other trusted health organizations.
- UveitisUveitisPubMed Health
Your browsing activity is empty.
Activity recording is turned off.
See more...
